Dr Agarwals Eye Hospital Ltd
Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]
- Market Cap ₹ 2,502 Cr.
- Current Price ₹ 5,323
- High / Low ₹ 7,300 / 3,500
- Stock P/E 43.3
- Book Value ₹ 446
- Dividend Yield 0.11 %
- ROCE 17.5 %
- ROE 29.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 32.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.2%
Cons
- Stock is trading at 11.9 times its book value
- Company might be capitalizing the interest cost
- Promoters have pledged or encumbered 55.4% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 414 | |
102 | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 290 | |
Operating Profit | 11 | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 120 | 124 |
OPM % | 9% | 13% | 13% | 15% | 16% | 18% | 27% | 22% | 29% | 28% | 29% | 30% | 30% |
3 | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 5 | |
Interest | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 15 | 15 |
Depreciation | 6 | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 40 |
Profit before tax | 4 | 5 | -0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 75 |
Tax % | 35% | -6% | -104% | 33% | 49% | 32% | 31% | 125% | 25% | 25% | 26% | 23% | |
2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 58 | |
EPS in Rs | 5.17 | 12.13 | 0.09 | 15.62 | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 | 122.98 |
Dividend Payout % | 23% | 10% | 940% | 10% | 8% | 6% | 0% | 0% | 6% | 4% | 3% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 18% |
3 Years: | 25% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 32% |
3 Years: | 31% |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 43% |
5 Years: | 88% |
3 Years: | 67% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | 29% |
5 Years: | 30% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Reserves | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 |
28 | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | |
20 | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | |
Total Liabilities | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | |
CWIP | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
41 | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | |
Total Assets | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | |
-11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | |
-3 | -5 | -0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | |
Net Cash Flow | -2 | -1 | 0 | 0 | -0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 19 | 19 | 24 | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 |
Inventory Days | 96 | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 |
Days Payable | 137 | 360 | 371 | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 |
Cash Conversion Cycle | -22 | -103 | -146 | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 |
Working Capital Days | -52 | -31 | -39 | -25 | -39 | -22 | -34 | -70 | -58 | -50 | -63 | -51 |
ROCE % | 17% | 19% | 18% | 29% | 32% | 34% | 30% | 11% | 20% | 19% | 18% | 18% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct
-
Closure of Trading Window
26 Sep - Trading window closed from Sept 30, 2025 until 48 hours after unaudited quarter results declaration.
-
Announcement under Regulation 30 (LODR)-Allotment
26 Sep - Allotment of 1,32,827 shares to AHCL at ₹5,270 each on Sept 26, 2025; proceeds ₹69,99,98,290.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 Sep
- Shareholder Meeting / Postal Ballot-Outcome of AGM 24 Sep
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025TranscriptNotesPPT
Services Offered
The company's centers offer comprehensive services in the eye-care segment including cataract, glaucoma, laser correction, corner and refractive, retina, squint, etc. [1]